Vorinostat, a potent non-selective HDAC inhibitor, has earned approval from the US Food and Drug Administration (FDA) for treating cutaneous T-cell lymphoma. This evidence concerns the gene HDAC9 and primary cutaneous T-cell non-Hodgkin lymphoma.